Immunome to Present at 2024 Bank of America Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Immunome, Inc.

Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, and radioligand therapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.

For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508531812/en/

Investor Contact
Max Rosett
Interim Chief Financial Officer
[email protected]

Source: Immunome, Inc.

You May Also Be Interested In

• Alibaba Group Announced Pricing of HK$80 Billion Placing of New Shares in Hong Kong
• Sergio V. Crowley Publishes Operations Research Framework for Industrial Capital Deployment
• DREAMO and DREAMOSIS Bring the Collectible Character Into a New Physical-Digital World